標(biāo)題: Titlebook: Gene Therapy for HIV and Chronic Infections; Ben Berkhout,Hildegund C.J. Ertl,Marc S. Weinberg Book 2015 American Society of Gene and Cell [打印本頁(yè)] 作者: 貪吃的人 時(shí)間: 2025-3-21 18:21
書目名稱Gene Therapy for HIV and Chronic Infections影響因子(影響力)
書目名稱Gene Therapy for HIV and Chronic Infections影響因子(影響力)學(xué)科排名
書目名稱Gene Therapy for HIV and Chronic Infections網(wǎng)絡(luò)公開度
書目名稱Gene Therapy for HIV and Chronic Infections網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Gene Therapy for HIV and Chronic Infections被引頻次
書目名稱Gene Therapy for HIV and Chronic Infections被引頻次學(xué)科排名
書目名稱Gene Therapy for HIV and Chronic Infections年度引用
書目名稱Gene Therapy for HIV and Chronic Infections年度引用學(xué)科排名
書目名稱Gene Therapy for HIV and Chronic Infections讀者反饋
書目名稱Gene Therapy for HIV and Chronic Infections讀者反饋學(xué)科排名
作者: 豐富 時(shí)間: 2025-3-21 23:40
Recent Advances in Use of Gene Therapy to Treat Hepatitis B Virus Infection,with serious complications of cirrhosis and liver cancer. Currently available treatments are modestly effective and advancing novel therapeutic strategies is a medical priority. Stability of the viral cccDNA replication intermediate is a major factor that has impeded the development of therapies tha作者: TAG 時(shí)間: 2025-3-22 01:13 作者: Medicaid 時(shí)間: 2025-3-22 08:08 作者: NATTY 時(shí)間: 2025-3-22 10:28
HIV and Ribozymes,As to more complex functions in cellular protein synthesis and gene regulation, ribozymes play important roles in all forms of life. Several naturally existing ribozymes have been modified for use as therapeutics in different conditions, with HIV-1 infection being one of the most studied. This chapt作者: PAD416 時(shí)間: 2025-3-22 15:16 作者: PAD416 時(shí)間: 2025-3-22 20:42
Synthetic DNA Approach to Cytomegalovirus Vaccine/Immune Therapy,is a major cause of congenital abnormalities in newborns, contributes to development of childhood cerebral palsy and medulloblastoma, can result in severe disease in immunocompromised patients, and is a major impediment during successful organ transplantation. While CMV has been increasingly associa作者: 天氣 時(shí)間: 2025-3-22 22:52 作者: 迷住 時(shí)間: 2025-3-23 04:03
HIV Latency and the Noncoding RNA Therapeutic Landscape,ent infection. The virus integrates into the genome of infected CD4+ cells and, in a subpopulation of cells, adopts a transcriptionally silent state, a process referred to a viral latency. This property makes it exceedingly difficult to therapeutically target the virus and eradicate infection. If le作者: Reservation 時(shí)間: 2025-3-23 06:37 作者: 名字的誤用 時(shí)間: 2025-3-23 09:42
,Aptamer–siRNA Chimeras for HIV,vels to below the detection limit and the survival rate of HIV-1 infected patients has been improving, long-term cART holds the potential to cause a number of chronic diseases. RNA interference (RNAi) is considered as a powerful method for developing new generation of therapeutics. Discovery of smal作者: 我怕被刺穿 時(shí)間: 2025-3-23 16:37
Ben Berkhout,Hildegund C.J. Ertl,Marc S. WeinbergThis book focuses on gene therapy and gene transfer approaches to prevent or treat chronoic virus infections.Discusses a collection of molecular antiviral strategies (ribozymes, RNAi, RNAu, aptamers, 作者: arbiter 時(shí)間: 2025-3-23 21:57 作者: Verify 時(shí)間: 2025-3-23 23:40
978-1-4939-4865-9American Society of Gene and Cell Therapy 2015作者: Hyaluronic-Acid 時(shí)間: 2025-3-24 04:07
Gene Therapy for HIV and Chronic Infections978-1-4939-2432-5Series ISSN 0065-2598 Series E-ISSN 2214-8019 作者: 發(fā)出眩目光芒 時(shí)間: 2025-3-24 07:23
Correction to: Political Parties,ected people in total, making it one of the major global health problems. In a minority of cases HCV is cleared spontaneously, but in most of the infected individuals infection progresses to a chronic state associated with high risk to develop liver cirrhosis, hepatocellular cancer, or liver failure作者: 排他 時(shí)間: 2025-3-24 12:53 作者: Enteropathic 時(shí)間: 2025-3-24 17:11 作者: jarring 時(shí)間: 2025-3-24 19:59 作者: 免費(fèi) 時(shí)間: 2025-3-25 00:17 作者: Harpoon 時(shí)間: 2025-3-25 06:19 作者: 課程 時(shí)間: 2025-3-25 10:17 作者: PLE 時(shí)間: 2025-3-25 13:18 作者: CRACK 時(shí)間: 2025-3-25 18:19 作者: 流逝 時(shí)間: 2025-3-25 21:42
G. Bradley Bookatz M.D.,Spero G. Karas M.D.n inhibitors. Antiviral genes encoding either membrane-anchored (ma) or secreted (iSAVE) C peptides have been engineered and allow direct in vivo production of the therapeutic peptides by genetically modified host cells. Membrane-anchored C peptides expressed in the HIV-1 target cells by T-cell or h作者: LATER 時(shí)間: 2025-3-26 00:25 作者: 外露 時(shí)間: 2025-3-26 05:00 作者: intuition 時(shí)間: 2025-3-26 09:09 作者: Counteract 時(shí)間: 2025-3-26 14:16 作者: Mercurial 時(shí)間: 2025-3-26 18:08 作者: UTTER 時(shí)間: 2025-3-26 21:50
Synthetic DNA Approach to Cytomegalovirus Vaccine/Immune Therapy, an efficacious vaccine would be highly valuable in reducing human morbidity and mortality as well as saving billions of dollars in annual health-care costs and disability adjusted life years (DALY) in the developing world. Therefore, the development of a safe efficacious CMV vaccine or immune thera作者: 手術(shù)刀 時(shí)間: 2025-3-27 02:51
Vector-Mediated Antibody Gene Transfer for Infectious Diseases,potent broadly cross-neutralizing HIV-1-specific antibodies into the clinic. The gene transfer products demonstrate a potency and breadth identical to the original product. This strategy eliminates the need for immunogen design and interaction with the adaptive immune system to generate protection, 作者: Prognosis 時(shí)間: 2025-3-27 08:54
HIV Latency and the Noncoding RNA Therapeutic Landscape,ion in human cells and play an active role in gene expression. Lastly, we explore therapeutic modalities based on expressed RNAs that are capable of countering infection, transcriptionally regulating the virus, and suppressing or activating the latent state.作者: goodwill 時(shí)間: 2025-3-27 13:28 作者: venous-leak 時(shí)間: 2025-3-27 16:25 作者: Interregnum 時(shí)間: 2025-3-27 18:06 作者: inventory 時(shí)間: 2025-3-27 23:07 作者: 討好女人 時(shí)間: 2025-3-28 02:05 作者: glomeruli 時(shí)間: 2025-3-28 06:22
https://doi.org/10.1007/1-4020-3345-1esigner transcription activator-like effector nucleases (TALENs) and repressor TALEs (rTALEs) have shown potential as a mode of inactivating cccDNA. In this article, we review the recent advances that have been made in HBV gene therapy, with a particular emphasis on the potential anti-HBV therapeuti作者: assent 時(shí)間: 2025-3-28 11:45 作者: custody 時(shí)間: 2025-3-28 15:11 作者: 不可知論 時(shí)間: 2025-3-28 20:43 作者: 商議 時(shí)間: 2025-3-28 23:56 作者: 控訴 時(shí)間: 2025-3-29 07:04
https://doi.org/10.1007/978-3-642-58274-5ion in human cells and play an active role in gene expression. Lastly, we explore therapeutic modalities based on expressed RNAs that are capable of countering infection, transcriptionally regulating the virus, and suppressing or activating the latent state.作者: sperse 時(shí)間: 2025-3-29 10:45
G. Bradley Bookatz M.D.,Spero G. Karas M.D.have the crucial advantage of not only protecting genetically modified cells from HIV-1 infection, but also neighboring cells, thus suppressing virus replication even if only a small fraction of cells is genetically modified. Accordingly, various cell types can be considered as potential in vivo pro作者: 爆炸 時(shí)間: 2025-3-29 12:43
Richard H. Bennett,Matthew H. Hulbertolecular interactions. SELEX technology enabled to isolate highly target specific aptamers from a random sequence oligonucleotide library. A number of aptamers for HIV-1 proteins as well as host proteins that interact with HIV-1 have been developed and some of them have potent viral neutralization a作者: 女上癮 時(shí)間: 2025-3-29 19:20
0065-2598 ular antiviral strategies (ribozymes, RNAi, RNAu, aptamers, This book centers ?on gene therapy and gene transfer approaches to prevent or treat chronic virus infections. The main focus is on the Big Three: human immunodeficiency virus (HIV-1), hepatitis B virus (HBV) and hepatitis C virus (HCV). Amp作者: 犬儒主義者 時(shí)間: 2025-3-29 21:33 作者: 小丑 時(shí)間: 2025-3-30 01:16 作者: Hemiparesis 時(shí)間: 2025-3-30 07:44
Gene Therapy Strategies to Block HIV-1 Replication by RNA Interference,rgeting host mRNAs that encode important viral cofactors, to the setup of appropriate preclinical test systems. Finally, we briefly discuss the relevance of this topic for other viral pathogens that cause a chronic infection in humans.作者: STANT 時(shí)間: 2025-3-30 08:53
https://doi.org/10.1057/9781137443601nhance the antiviral effect of ribozymes are also presented and the results from clinical trials conducted to date are summarized. Studies on anti-HIV-1 ribozymes have provided valuable information on the optimal expression strategies and clinical protocols for RNA gene therapy and remain competitive candidates for future therapy.
